The Potential of Targeting Anti-CD3 in Progressive Multiple Sclerosis: Tanuja Chitnis, MD
The associate neurologist at Brigham and Women’s Hospital provided background on a new case study of a patient with progressive MS who showed positive outcomes using foralumab, an anti-CD3 targeting agent. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
"We’ve also been doing nose and throat evaluations every 3 weeks and those have all been normal, which is heartening. The patient feels stable and somewhat improved, and we’ve seen that his motor scores, [and] pyramidal scores have improved on treatment, so we’re encouraged by that. He’s received over 6 months of treatment and is doing well.”
As there is need for medications in patients with progressive multiple sclerosis (MS), investigators have turned to targeting a new pathway using anti-CD3 therapy. A new case study, led by Tanuja Chitnis, MD, evaluated the effects of nasal foralumab (Tiziana Life Sciences), a fully human anti-CD3 monoclonal antibody, in a patient with nonactive secondary progressive MS. The 61-year-old man had been diagnosed for over 20 years and continued to progress while on ocrelizumab (Ocrevus; Genentech), the only FDA-approved therapeutic for this patient population.
Treatment with foralumab was initiated in May 2021 and was continued for 6 months with a 7-week washout period after 3 months. Presented at the
To learn more about the findings, including some of the more fine-tuned details of the patient experience, NeurologyLive® sat down with Chitnis. The associate neurologist at Brigham and Women’s Hospital, and professor of neurology at Harvard Medical School explained the origin and potential of anti-CD3 therapy, along with the phase 1 findings that sparked the research interest.
REFERENCE
1. Chitnis T, Singhal T, Zurawski J, et al. Nasal anti-CD3 monoclonal antibody (foralumab) reduces PET microglial activation and blood inflammatory biomarkers in a patient with non-active secondary progressive MS. Presented at: CMSC Annual Meeting, 2022; June 1-4; National Harbor, MD. LB
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
